tetano
Editor, Senior Moderator
Sci Rep. 2015 Jun 10;5:11233. doi: 10.1038/srep11233.
[h=1]A live attenuated vaccine prevents replication and transmission of H7N9 virus in mammals.[/h] Kong H[SUP]1[/SUP], Zhang Q[SUP]2[/SUP], Gu C[SUP]1[/SUP], Shi J[SUP]1[/SUP], Deng G[SUP]1[/SUP], Ma S[SUP]1[/SUP], Liu J[SUP]1[/SUP], Chen P[SUP]1[/SUP], Guan Y[SUP]1[/SUP], Jiang Y[SUP]1[/SUP], Chen H[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The continued spread of the newly emerged H7N9 viruses among poultry in China, together with the emergence of drug-resistant variants and the possibility of human-to-human transmission, has spurred attempts to develop an effective vaccine. An MF59-adjuvant H7N9 inactivated vaccine is reported to be well-tolerated and immunogenic in humans; however a study in ferrets indicated that while a single dose of the inactivated H7N9 vaccine reduced disease severity, it did not prevent virus replication and transmission. In this study, we used reverse genetics to produce a cold-adapted, live attenuated H7N9 vaccine (H7N9/AAca) that contains wild-type HA and NA genes from AH/1, and the backbone of the cold-adapted influenza H2N2 A/Ann Arbor/6/60 virus (AAca). H7N9/AAca was attenuated in mice and ferrets, and induced robust neutralizing antibody responses in rhesus mice, ferrets, and guinea pigs immunized once or twice intranasally. The animals immunized twice were completely protected from H7N9 virus challenge. Importantly, the animals vaccinated once were fully protected from transmission when exposed to or in contact with the H7N9 virus-inoculated animals. These results demonstrate that a cold-adapted H7N9 vaccine can prevent H7N9 virus transmission; they provide a compelling argument for further testing of this vaccine in human trials.
PMID: 26058711 [PubMed - in process]
[h=1]A live attenuated vaccine prevents replication and transmission of H7N9 virus in mammals.[/h] Kong H[SUP]1[/SUP], Zhang Q[SUP]2[/SUP], Gu C[SUP]1[/SUP], Shi J[SUP]1[/SUP], Deng G[SUP]1[/SUP], Ma S[SUP]1[/SUP], Liu J[SUP]1[/SUP], Chen P[SUP]1[/SUP], Guan Y[SUP]1[/SUP], Jiang Y[SUP]1[/SUP], Chen H[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The continued spread of the newly emerged H7N9 viruses among poultry in China, together with the emergence of drug-resistant variants and the possibility of human-to-human transmission, has spurred attempts to develop an effective vaccine. An MF59-adjuvant H7N9 inactivated vaccine is reported to be well-tolerated and immunogenic in humans; however a study in ferrets indicated that while a single dose of the inactivated H7N9 vaccine reduced disease severity, it did not prevent virus replication and transmission. In this study, we used reverse genetics to produce a cold-adapted, live attenuated H7N9 vaccine (H7N9/AAca) that contains wild-type HA and NA genes from AH/1, and the backbone of the cold-adapted influenza H2N2 A/Ann Arbor/6/60 virus (AAca). H7N9/AAca was attenuated in mice and ferrets, and induced robust neutralizing antibody responses in rhesus mice, ferrets, and guinea pigs immunized once or twice intranasally. The animals immunized twice were completely protected from H7N9 virus challenge. Importantly, the animals vaccinated once were fully protected from transmission when exposed to or in contact with the H7N9 virus-inoculated animals. These results demonstrate that a cold-adapted H7N9 vaccine can prevent H7N9 virus transmission; they provide a compelling argument for further testing of this vaccine in human trials.
PMID: 26058711 [PubMed - in process]